RNA Production Co-op
About the job
- Currently pursuing a master's degree in life sciences, molecular biology, biochemistry, biomedical engineering, or biotechnology, with plans to graduate by Spring 2027 or 2028.
- Must be permanently authorized to work in the United States and not require employment visa sponsorship now or in the future.
- Must remain enrolled at an accredited college or university throughout the co-op/internship.
- Must be able to relocate to the office location and work 40 hours per week, Monday through Friday, for the full duration.
- Experience in nucleic acid synthesis, handling under RNase-free conditions, or application, with hands-on experience in messenger RNA production or characterization is preferred.
- Hands-on experience in capillary and gel electrophoresis is an asset.
- Hands-on experience in analytical and molecular biology methods relevant to messenger RNA is an asset.
- Support messenger RNA production efforts for messenger RNA drug targets, including batch production, characterization, and optimization of messenger RNA processes.
- Synthesize and purify a wide range of messenger RNA constructs in parallel to support rapid program progression.
- Accurately and reproducibly perform analytical characterization for the full release panel for messenger RNA drug substance.
- Contribute to optimizing messenger RNA sequence design, production, and purification.
- Contribute to platform projects by evaluating and implementing new technologies and optimizing existing workflows.
- Prepare technical reports, presentations, and recommendations for management and other stakeholders.
- Perform the position primarily in a laboratory setting.
- Desire to work in a team-first, fast-paced environment, learn new skills, and efficiently solve problems.
- Attention to detail and meticulous record keeping.
- Manage time effectively and manage multiple projects at one time.
About the company
Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Get referred to Sanofi
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
- June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
- Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.
What critics are saying
- Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
- Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
- Dupixent concentration makes 2030s patent loss an existential revenue shock.
What makes Sanofi unique
- Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
- October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
- Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Health Insurance
- Professional Development Budget
- Parental Leave